Jaundice resident survival guide: Difference between revisions
Line 175: | Line 175: | ||
| | | | ||
*Suspect for Dubin-Johnson syndrome before considering surgery if the healthy patient with long-standing [[conjugated]] [[hyperbilirubinemia]], other normal liver function tests, and a non visualized gallbladder.<br> | *Suspect for Dubin-Johnson syndrome before considering surgery if the healthy patient with long-standing [[conjugated]] [[hyperbilirubinemia]], other normal liver function tests, and a non visualized gallbladder.<br> | ||
* Hepatic architecture is normal but there is an accumulation of hepatic pigment compatible with melanin in patients with Dubin-Johnson syndrome<br> | * Hepatic architecture is normal but there is an accumulation of hepatic pigment compatible with [[melanin]] in patients with Dubin-Johnson syndrome<br> | ||
*In Rotor's syndrome the gallbladder opacifies normally with cholecystographic dye and no pigmentation be seen in the liver. | *In Rotor's syndrome the [[gallbladder]] opacifies normally with cholecystographic dye and no pigmentation be seen in the liver. | ||
|- | |- | ||
|'''Managment of conjugated & unconjugated hyperbilirubinemia jaundice with | |'''Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ⇈[[AST]]/[[ALT]] out of proportion to [[ALP]]'''' || | ||
*History of recent travel<br> | *History of recent travel<br> | ||
* Social history: Alcohol, sexual history<br> | * Social history: Alcohol, sexual history<br> | ||
* Family history of Wilson's disease or hemochromatosis<br> | * Family history of [[Wilson's disease]] or [[hemochromatosis]]<br> | ||
*Review medications<br> | *Review medications<br> | ||
*Pregnancy test<BR>HELLP, | *Pregnancy test<BR>[[HELLP syndrome]], [[AFLP]]<BR> | ||
*Toxicology screen<br>Acetaminophen level<br> | *Toxicology screen<br>Acetaminophen level<br> | ||
*Mild elevation in aminotransferase levels in female patients with concomitant autoimmune disorders (e.g., autoimmune thyroiditis, connective tissue diseases) is suggestive of autoimmune hepatitis.<br> | *Mild elevation in aminotransferase levels in female patients with concomitant [[autoimmune]] disorders (e.g., [[autoimmune thyroiditis]], connective tissue diseases) is suggestive of autoimmune hepatitis.<br> | ||
*Consider work-up for rare cases<br>Liver biopsy if results negative<br> | *Consider work-up for rare cases<br>Liver biopsy if results negative<br> | ||
*Ischemic acute liver damage is more likely in patients with concomitant clinical conditions such as sepsis or low-flow hemodynamic state or right-sided heart failure| | *Ischemic acute liver damage is more likely in patients with concomitant clinical conditions such as sepsis or low-flow hemodynamic state or right-sided heart failure| | ||
| | | | ||
*Viral hepatitis<br>Hepatitis A: mostly self-limiting <br> Hepatitis B treated with antiviral medications<br>Hepatitis C is treated with interferons<br>Other Viral infections like EBV, CMV, HSV are treated with Antiviral medications <br> | *[[Viral hepatitis]]<br>Hepatitis A: mostly self-limiting <br> [[Hepatitis B]] treated with antiviral medications<br>[[Hepatitis C]] is treated with interferons<br>Other Viral infections like [[EBV]], [[CMV]], [[HSV]] are treated with Antiviral medications <br>[[Alcohol hepatitis]]: Alcohol abstinence, [[glucocorticoids]], [[pentoxifylline]]<br> | ||
* Wilson"s disease: chelating agents such as D-penicillamine<br> | * Wilson"s disease: chelating agents such as D-penicillamine<br> | ||
* Drug toxicity treatment(e.g. Acetaminophen, Isoniazid<br> | * Drug toxicity treatment(e.g. [[Acetaminophen]], [[Isoniazid]]<br> | ||
* Autoimmune hepatitis treatment with glucocorticoids | * Autoimmune hepatitis treatment with glucocorticoids | ||
|- | |- | ||
|'''Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ⇈ | |'''Managment of conjugated & unconjugated [[hyperbilirubinemia]] jaundice with ⇈ [[AlP]] out of proportion to [[AST]]/[[ALT]]'''|| | ||
*History of intermittent right upper quadrant pain radiating to the back or right shoulder favors gallstones, fever and chills suggest cholangitis.<br> | *History of intermittent right upper quadrant pain radiating to the back or right shoulder favors [[gallstones]], fever and chills suggest [[cholangitis]].<br> | ||
* History of biliary tract surgery within 2 years should alert the physician to possible biliary stricture. <br> | * History of biliary tract surgery within 2 years should alert the physician to possible [[biliary]] stricture. <br> | ||
*History recent weight loss, constant epigastric or right upper quadrant pain radiating to the back suggests malignancy<br> | *History recent weight loss, constant epigastric or right upper quadrant pain radiating to the back suggests malignancy<br> | ||
*Icteric patient with extrahepatic obstruction due to gallstones or postsurgical biliary stricture has usually had acute symptoms for less than 2 weeks<br> | *Icteric patient with extrahepatic obstruction due to gallstones or postsurgical biliary stricture has usually had acute symptoms for less than 2 weeks<br> | ||
*Those with carcinoma, chronic pancreatitis, or primary sclerosing cholangitis have had symptoms of longer duration<br> | *Those with carcinoma, [[chronic pancreatitis]], or [[primary sclerosing cholangitis]] have had symptoms of longer duration<br> | ||
* A middle-aged woman with a history of itching and autoimmune disease raises the suspicion of primary biliary cirrhosis<br>More than half the people with primary biliary | * A middle-aged woman with a history of itching and autoimmune disease raises the suspicion of [[primary biliary cirrhosis]]<br>More than half the people with primary biliary cirrhosis do not have any symptoms when diagnosed. Symptoms develop over the next five to 20 years. Those who do have symptoms at diagnosis typically have poorer outcomes.<br> | ||
*Commonly used drugs such as antihypertensives (e.g., angiotensin-converting enzyme inhibitors) or hormones (e.g., estrogen) may cause cholestasis<br> | *Commonly used drugs such as [[antihypertensives]] (e.g., [[angiotensin-converting enzyme inhibitors]]) or [[hormones]] (e.g., estrogen) may cause [[cholestasis]]<br> | ||
*Abnormal | *Abnormal [[ALP]] levels may be a sign of metastatic cancer of the liver, [[lymphoma]] or infiltrative diseases such as [[sarcoidosis]].<br> | ||
* H/O inflammatory bowel disease (most commonly ulcerative colitis) suggests the presence of primary sclerosing cholangitis since about 70% of these cases are associated with inflammatory bowel disease<br> | * H/O inflammatory bowel disease (most commonly ulcerative colitis) suggests the presence of primary sclerosing cholangitis since about 70% of these cases are associated with inflammatory bowel disease<br> | ||
*TPN is associated with ↑ Alk-p and GGT level.| | *TPN is associated with ↑ Alk-p and GGT level.| | ||
| | | | ||
*Obstruction removal by ERCP, PTC, Surgery (e.g.Cholecystectomy or Palliative Bypass procedures such as hepaticojejunostomy if stenting has failed in patients with tumors)<br> | *Obstruction removal by [[ERCP]], [[PTC]], Surgery (e.g.[[Cholecystectomy]] or Palliative Bypass procedures such as hepaticojejunostomy if stenting has failed in patients with tumors)<br> | ||
*Primary biliary cholangitis management: no cure for primary biliary cholangitis, but medications are available for slow the progression and prevent complications of the disease: Ursodeoxycholic acid (UDCA), Obeticholic acid (Ocaliva), Fibrates, Liver transplantation may help prolongs life.<br> | *[[Primary biliary cholangitis]] management: no cure for primary biliary cholangitis, but medications are available for slow the progression and prevent complications of the disease: Ursodeoxycholic acid (UDCA), Obeticholic acid (Ocaliva), [[Fibrates]], Liver transplantation may help prolongs life.<br> | ||
*Treatments for primary sclerosing cholangitis focus on managing complications and monitoring liver damage. None of the medications has been found to slow or reverse the liver damage associated with this disease. | *Treatments for primary sclerosing cholangitis focus on managing complications and monitoring liver damage. None of the medications has been found to slow or reverse the liver damage associated with this disease. | ||
|- | |- | ||
|'''Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ↑ INR,↓ Alb,↓ PLT''' | | |'''Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ↑ INR,↓ Alb,↓ PLT''' | | ||
| | | | ||
*Cirrhotic patients with MELD Score> 15 should be referred to liver transplant center<br> | *Cirrhotic patients with [[MELD]] Score> 15 should be referred to liver transplant center<br> | ||
*Patients with MELD Score< 15 should be treated depending on compensated Cirrhosis or decompensated one| | *Patients with MELD Score< 15 should be treated depending on compensated [[Cirrhosis]] or decompensated one| | ||
| | | | ||
*Compensated Cirrhosis Mangament<br>Alochol abstinence<br> Antiviral medications for viral hepatitis<br> avoidance of hepatotoxic medications<br>vaccination<br> | *Compensated Cirrhosis Mangament<br>Alochol abstinence<br> Antiviral medications for viral hepatitis<br> avoidance of hepatotoxic medications<br>vaccination<br> | ||
*Decompensated Cirrhosis Managment<br>Managment of complications:<br>Varices, Ascites, Hepatorenal syndrome, Hepatic encephalopathy( Acute liver failure ) | *Decompensated Cirrhosis Managment<br>Managment of complications:<br>[[Varices]], [[Ascites]], [[Hepatorenal syndrome]], [[Hepatic encephalopathy]]( Acute liver failure ) | ||
|- | |- | ||
|} | |} |
Revision as of 19:12, 25 August 2020
Jaundice Resident Survival Guide |
---|
Overview |
Causes |
Diagnosis |
Treatment |
Do's |
Don'ts |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Roghayeh Marandi, M.D.[2]
Synonyms and keywords: Approach to jaundice, Jaundice workup, Jaundice management
Overview
The classic definition of Jaundice is a serum bilirubin level higher than 2.5 to 3 mg per dL (42.8 to 51.3 μper L) in conjunction with a clinical picture of yellow skin and sclera. The causes of jaundice can be classified under these categories by measuring total bilirubin and its conjugated and unconjugated levels determine where is the dysfunction of bilirubin metabolism.
Causes
Life Threatening Causes
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
- Ascending cholangitis
- Sepsis
- Acute liver failure (the combination of jaundice with hepatic encephalopathy)
Common Causes
Common causes of acute Jaundice[1]
- Gilbert syndrome
- Alcoholic hepatitis
- Viral hepatitis
- Obstructive Jaundice due to choledocholithiasis or malignancy
- Decompensated chronic liver disease
Common causes of chronic progressive jaundice
Diagnosis
Shown below is an algorithm summarizing the diagnosis of jaundice.[2][3][4][5]
Characterize the jaundice duration and frequency ❑ Duration: short versus long ❑ Frequency: episodic vesus constant | |||||||||||||||||||||||||||||||||||||||||||||||
Ask about associated symptoms ❑ Abdominal pain (episodic or constant) ❑ Abdominal distension ❑ Fever ❑ Clay colored stool ❑ Dark urine ❑ Weight gain or loss ❑ Anorexia ❑ Dyspepsia ❑ Arthralgia ❑ Myalgia ❑ Back pain ❑ Rash ❑ Confusion | |||||||||||||||||||||||||||||||||||||||||||||||
Inquire about ❑ Past medical history ❑ Blood disorder
❑ Family history of ❑ Medication history
❑ Recent travel history
| |||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient General Appearance ❑ Check for:
Skin exam
Cardiac exam
❑ Check gallbladder area if it is tender
❑ Splenomegaly can be seen in hemolytic states, Hodgkin’s lymphoma, portal hypertension
| |||||||||||||||||||||||||||||||||||||||||||||||
Order ❑ Blood tests
❑ Urine
| |||||||||||||||||||||||||||||||||||||||||||||||
Isolated unconjugated hyperbilirubinemia | Isolated conjugated hyperbilirubinemia | Unconjugated & conjugated hyperbilirubinemia | |||||||||||||||||||||||||||||||||||||||||||||
❑ Inquire about any recent trauma hematoma blood transfusion | ❑ Dubin-Johnson syndrome ❑ Rotor syndrome | ||||||||||||||||||||||||||||||||||||||||||||||
If none of them | With Liver enzyme changes | with ↑ INR,↓ Alb,↓ PLt | |||||||||||||||||||||||||||||||||||||||||||||
❑ Check Hb,LDH,Haptoglobin,Recticulocyte count | If ⇈AST/ALT out of proportion to ALK-P | If ⇈Alk-P out of proportion to AST/ALT | Suggestive of cCirrhosis Additional tests to find the cause of cirrhosis Hepatitis serology Iron panel Abdominal Ultrasound Workup for Automimmune hepatitis, NAFLD,Hemochromatosis & other causes of cirrhosis | ||||||||||||||||||||||||||||||||||||||||||||
Abnormal | Normal | Hepatocellular pattern | Cholestatic pattern | ||||||||||||||||||||||||||||||||||||||||||||
Start workup of hemolytic anemia with blood smear & coombs test | ❑ Gilbert syndrome ❑ Crigler-Najjar type I,II | Additional work-up for specific diseases Viral hepatitis serology(e.g. HAV,HBV,HCV) Toxicology screen Acetaminophen level Cereuloplasmin if patient<40 years of age Autoantibodies (ANA,Anti-sm,LKM,...) Ferritin & TIBC HbA1c Pregnancy test a1-antitrypsin ❑Consider work-up for rare cases Liver biopsy if results negative | Ultrasound | ||||||||||||||||||||||||||||||||||||||||||||
Consider following based on the results: ❑ Sickle cell disease ❑ Hereditary spherocytosis ❑ G6PD deficiency ❑ Medications effect( Rifampicin, Probencid) ❑ Immune-mediated hemolysis | Consider following based on the results: ❑ Viral hepatitis ❑ NAFLD (Non-alcoholic liver disease) ❑ ppAlcoholic liver disease]] ❑ Metabolic/genetic diseases Hereditary hemochromatosis ppWilson's disease]] ppAlpha-1 antitrypsin deficiency]] ❑ Drug-induced and supplemental-induced injury Acetaminophen, kavakava, Vinyl cholride ❑ Pregnancy AFLP,HELLP ❑ Autoimmune hepatitis ❑ Ischemic hepatitis | Bile ducts dilated | Bile ducts not dilated | ||||||||||||||||||||||||||||||||||||||||||||
ERCP/CT | Additional work-up for intrahepatic cholestasis | ||||||||||||||||||||||||||||||||||||||||||||||
❑ Common bile duct stones ❑ Biliray stricture ❑ Worms/flukes ❑ Extrahepatic sources: ❑ Cholangiocarcinoma ❑ Pancreatic cancer | Consider following based on the results: | ||||||||||||||||||||||||||||||||||||||||||||||
Treatment
Type of hyperbilirubinemia | Diagnostic Indicators | Management Recommendations |
---|---|---|
Managment of isolated unconjugated jaundice, hemolytic |
hemolysis
|
|
Managment of isolated unconjugated jaundice, Non-hemolytic |
|
|
Managment of isolated conjugated jaundice |
|
|
Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ⇈AST/ALT out of proportion to ALP' |
|
|
Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ⇈ AlP out of proportion to AST/ALT |
|
|
|
Do's
- Alcohol Use: Screen for alcohol use disorders in all patients
- Medications: Discuss the safety of limited (2 gram/day) acetaminophen use, review pharmacologic history, and discontinue medications that cause hemolysis or drug-induced hepatitis.
- Treat of underlying disease conditions
- Liver Transplant Referral: Refer early when a patient needs
- Palliative Care: Address goals of care and refer to palliative care early especially for patients with tumors
Don'ts
- Forget to discuss medication to avoid, especially in patients with G6PD or drug-induced hepatitis.
- Delay palliative care until the patient is in a critical state.
- Delay referring a patient to the liver transplant center until the patient is hospitalized in life-threatening condition
References
- ↑ Warner, Ben; Wilkinson, Mark (2017). "Acute jaundice": 150–154. doi:10.1002/9781119389613.ch23.
- ↑ Giannini EG, Testa R, Savarino V (February 2005). "Liver enzyme alteration: a guide for clinicians". CMAJ. 172 (3): 367–79. doi:10.1503/cmaj.1040752. PMC 545762. PMID 15684121.
- ↑ Walker HK, Hall WD, Hurst JW, Stillman AE. PMID 21250253. Missing or empty
|title=
(help) - ↑ Gondal B, Aronsohn A (December 2016). "A Systematic Approach to Patients with Jaundice". Semin Intervent Radiol. 33 (4): 253–258. doi:10.1055/s-0036-1592331. PMC 5088098. PMID 27904243.
- ↑ Syhavong B, Rasachack B, Smythe L, Rolain JM, Roque-Afonso AM, Jenjaroen K, Soukkhaserm V, Phongmany S, Phetsouvanh R, Soukkhaserm S, Thammavong T, Mayxay M, Blacksell SD, Barnes E, Parola P, Dussaix E, Raoult D, Humphreys I, Klenerman P, White NJ, Newton PN (July 2010). "The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos". Trans. R. Soc. Trop. Med. Hyg. 104 (7): 475–83. doi:10.1016/j.trstmh.2010.03.002. PMC 2896487. PMID 20378138.
- ↑ Göring HD (April 1989). "[Comment on the response by R. Rüdlinger to a question from general practice: the importance of warts in kidney transplant patients]". Hautarzt (in German). 40 (4): 243–4. PMID 2659553.